Syk is a novel target of arsenic trioxide (ATO) and is involved in the toxic effect of ATO in human neutrophils

Toxicology in Vitro

Volumn 24, Issue 3, 2010, Pages 936-941

  Antoine, Francis ^a   Ennaciri, Jamila ^a   Girard, Denis ^a  

^a UNIVERSITÉ LAVAL   (Canada)

Author keywords

Arsenic; Immunotoxicity; Inflammation; Neutrophils; Syk kinase

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; ARSENIC TRIOXIDE; CD66B ANTIGEN; COMPLEMENT COMPONENT C3B RECEPTOR; LYMPHOCYTE ANTIGEN; PICEATANNOL; PROTEIN KINASE SYK; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL ADHESION; CELL SURFACE; CONTROLLED STUDY; DEGRANULATION; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; NEUTROPHIL; PHAGOCYTOSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS; ANTISENSE ELEMENTS (GENETICS); APOPTOSIS; ARSENICALS; CELL ADHESION; CELL DEGRANULATION; CELL SEPARATION; ENZYME ACTIVATION; ENZYME INHIBITORS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE PROTEINS; NEUTROPHILS; OXIDES; PHAGOCYTOSIS; PHOSPHORYLATION; PROTEIN-TYROSINE KINASES; SPLEEN; STILBENES;

EID: 77649189588     PISSN: 08872333     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tiv.2009.11.011     Document Type: Article

References (38)

1. Abram C.L., and Lowell C.A. Convergence of immunoreceptor and integrin signaling. Immunological Reviews 218 (2007) 29-44
2. Berton G., Mocsai A., and Lowell C.A. Src and Syk kinases: key regulators of phagocytic cell activation. Trends in Immunology 26 (2005) 208-214
3. 2-terminal MAPK but not extracellular signal-regulated kinases-1/2. Journal of Leukocyte Biology 84 (2008) 1613-1622
4. Binet F., Cavalli H., Moisan E., and Girard D. Arsenic trioxide (AT) is a novel human neutrophil pro-apoptotic agent: effects of catalase on AT-induced apoptosis, degradation of cytoskeletal proteins and de novo protein synthesis. British Journal of Haematology 132 (2006) 349-358
5. Binet F., Chiasson S., and Girard D. Arsenic trioxide induces de novo protein synthesis of annexin-1 in neutrophils: association with a heat shock-like response and not apoptosis. British Journal of Haematology 140 (2008) 454-463
6. Crowley M.T., Costello P.S., Fitzer-Attas C.J., Turner M., Meng F., Lowell C., Tybulewicz V.L., and DeFranco A.L. A critical role for Syk in signal transduction and phagocytosis mediated by Fcgamma receptors on macrophages. Journal of Experimental Medicine 186 (1997) 1027-1039
7. Fudala R., Krupa A., Matthay M.A., Allen T.C., and Kurdowska A.K. Anti-IL-8 autoantibody:IL-8 immune complexes suppress spontaneous apoptosis of neutrophils. American Journal of Physiology-Lung Cellular and Molecular Physiology 293 (2007) L364-L374
8. Girard D., Paquet M.E., Paquin R., and Beaulieu A.D. Differential effects of interleukin-15 (IL-15) and IL-2 on human neutrophils: modulation of phagocytosis, cytoskeleton rearrangement, gene expression, and apoptosis by IL-15. Blood 88 (1996) 3176-3184
9. Girard D., Paquin R., and Beaulieu A.D. Responsiveness of human neutrophils to interleukin-4: induction of cytoskeletal rearrangements, de novo protein synthesis and delay of apoptosis. Biochemical Journal 325 Pt 1 (1997) 147-153
10. Harnett M. Syk deficiency - a knockout for B-cell development. Immunology Today 17 (1996) 4
11. Hayes M.J., and Cambridge G. An IgM class anti-neutrophil cytoplasm antibody inhibits neutrophil adhesion and apoptosis via a Syk dependent signaling cascade. Molecular Immunology 41 (2004) 457-468
12. 2+-dependent production of superoxide. International Journal of Cancer 92 (2001) 518-526
13. Jog N.R., Rane M.J., Lominadze G., Luerman G.C., Ward R.A., and McLeish K.R. The actin cytoskeleton regulates exocytosis of all neutrophil granule subsets. American Journal of Physiology-Cell Physiology 292 (2007) C1690-C1700
14. Kajiguchi T., Yamamoto K., Iida S., Ueda R., Emi N., and Naoe T. Sustained activation of c-jun-N-terminal kinase plays a critical role in arsenic trioxide-induced cell apoptosis in multiple myeloma cell lines. Cancer Sciences 97 (2006) 540-545
15. Kasper B., Brandt E., Ernst M., and Petersen F. Neutrophil adhesion to endothelial cells induced by platelet factor 4 requires sequential activation of Ras, Syk, and JNK MAP kinases. Blood 107 (2006) 1768-1775
16. Majeed M., Caveggion E., Lowell C.A., and Berton G. Role of Src kinases and Syk in Fcgamma receptor-mediated phagocytosis and phagosome-lysosome fusion. Journal of Leukocyte Biology 70 (2001) 801-811
17. Miller Jr. W.H. Molecular targets of arsenic trioxide in malignant cells. The Oncologist 7 Suppl. 1 (2002) 14-19
18. Miller Jr. W.H., Schipper H.M., Lee J.S., Singer J., and Waxman S. Mechanisms of action of arsenic trioxide. Cancer Research 62 (2002) 3893-3903
19. Mocsai A., Zhou M., Meng F., Tybulewicz V.L., and Lowell C.A. Syk is required for integrin signaling in neutrophils. Immunity 16 (2002) 547-558
20. Moon K.D., Post C.B., Durden D.L., Zhou Q., De P., Harrison M.L., and Geahlen R.L. Molecular basis for a direct interaction between the Syk protein-tyrosine kinase and phosphoinositide 3-kinase. Journal of Biological Chemistry 280 (2005) 1543-1551
21. Munshi N.C., Tricot G., Desikan R., Badros A., Zangari M., Toor A., Morris C., Anaissie E., and Barlogie B. Clinical activity of arsenic trioxide for the treatment of multiple myeloma. Leukemia 16 (2002) 1835-1837
22. Ortiz-Stern A., and Rosales C. Fc gammaRIIIB stimulation promotes beta1 integrin activation in human neutrophils. Journal of Leukocyte Biology 77 (2005) 787-799
23. Potin S., Bertoglio J., and Breard J. Involvement of a Rho-ROCK-JNK pathway in arsenic trioxide-induced apoptosis in chronic myelogenous leukemia cells. FEBS Letters 581 (2007) 118-124
24. Raeder E.M., Mansfield P.J., Hinkovska-Galcheva V., Shayman J.A., and Boxer L.A. Syk activation initiates downstream signaling events during human polymorphonuclear leukocyte phagocytosis. Journal of Immunology 163 (1999) 6785-6793
25. Ramos A.M., Fernandez C., Amran D., Esteban D., de Blas E., Palacios M.A., and Aller P. Pharmacologic inhibitors of extracellular signal-regulated kinase (ERKs) and c-Jun NH(2)-terminal kinase (JNK) decrease glutathione content and sensitize human promonocytic leukemia cells to arsenic trioxide-induced apoptosis. Journal of Cellular Physiology 209 (2006) 1006-1015
26. Ratthe C., and Girard D. Interleukin-15 enhances human neutrophil phagocytosis by a Syk-dependent mechanism: importance of the IL-15Ralpha chain. Journal of Leukocyte Biology 76 (2004) 162-168
27. Ratthe C., Pelletier M., Chiasson S., and Girard D. Molecular mechanisms involved in interleukin-4 (IL-4)-induced human neutrophils: expression and regulation of suppressor of cytokine signaling (SOCS). Journal of Leukocyte Biology 81 (2007) 1287-1296
28. Sada K., Takano T., Yanagi S., and Yamamura H. Structure and function of Syk protein-tyrosine kinase. Journal of Biochemistry 130 (2001) 177-186
29. Schymeinsky J., Then C., and Walzog B. The non-receptor tyrosine kinase Syk regulates lamellipodium formation and site-directed migration of human leukocytes. Journal of Cellular Physiology 204 (2005) 614-622
30. Shim M.J., Kim H.J., Yang S.J., Lee I.S., Choi H.I., and Kim T. Arsenic trioxide induces apoptosis in chronic myelogenous leukemia K562 cells: possible involvement of p38 MAP kinase. Journal of Biochemistry and Molecular Biology 35 (2002) 377-383
31. Stenton G.R., Kim M.K., Nohara O., Chen C.F., Hirji N., Wills F.L., Gilchrist M., Hwang P.H., Park J.G., Finlay W., Jones R.L., Befus A.D., and Schreiber A.D. Aerosolized Syk antisense suppresses Syk expression, mediator release from macrophages, and pulmonary inflammation. Journal of Immunology 164 (2000) 3790-3797
32. Stenton G.R., Ulanova M., Dery R.E., Merani S., Kim M.K., Gilchrist M., Puttagunta L., Musat-Marcu S., James D., Schreiber A.D., and Befus A.D. Inhibition of allergic inflammation in the airways using aerosolized antisense to Syk kinase. Journal of Immunology 169 (2002) 1028-1036
33. Turner M., Schweighoffer E., Colucci F., Di Santo J.P., and Tybulewicz V.L. Tyrosine kinase SYK: essential functions for immunoreceptor signalling. Immunology Today 21 (2000) 148-154
34. Verma A., Mohindru M., Deb D.K., Sassano A., Kambhampati S., Ravandi F., Minucci S., Kalvakolanu D.V., and Platanias L.C. Activation of Rac1 and the p38 mitogen-activated protein kinase pathway in response to arsenic trioxide. Journal of Biological Chemistry 277 (2002) 44988-44995
35. Wong W.S., and Leong K.P. Tyrosine kinase inhibitors: a new approach for asthma. Biochimica et Biophysica Acta 1697 (2004) 53-69
36. Wong B.R., Grossbard E.B., Payan D.G., and Masuda E.S. Targeting Syk as a treatment for allergic and autoimmune disorders. Expert Opinion on Investigational Drugs 13 (2004) 743-762
37. Yousefi S., Hoessli D.C., Blaser K., Mills G.B., and Simon H.U. Requirement of Lyn and Syk tyrosine kinases for the prevention of apoptosis by cytokines in human eosinophils. Journal of Experimental Medicine 183 (1996) 1407-1414
38. Zarbock A., Lowell C.A., and Ley K. Spleen tyrosine kinase Syk is necessary for E-selectin-induced alpha(L)beta(2) integrin-mediated rolling on intercellular adhesion molecule-1. Immunity 26 (2007) 773-783